Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of the Efficacy of Viral Neutralizing Monoclonal Antibodies Tiksagevimab/Cilgavimab and Regdanvimab for Omicron Strain Dominance in Patients With COVID-19

NCT05982704 is registered in ClinicalTrials.gov with City Clinical Hospital No.52 of Moscow Healthcare Department as lead sponsor.

NCT NCT05982704
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05982704 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of the Efficacy of Viral Neutralizing Monoclonal Antibodies Tiksagevimab/Cilgavimab and Regdanvimab for Omicron Strain Dominance in Patients With COVID-19
Lead sponsor
City Clinical Hospital No.52 of Moscow Healthcare Department
Phase
Phase 4
Overall status
Unknown status
Start date
August 18, 2022
Completion date
November 1, 2023
Enrollment
82 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus infections